You are here
Welcome to Pfizer’s news section — designed to give you access to timely and relevant information about our company. In this section you will find information and resources for journalists, including current and archived Pfizer press releases, a full company press kit, and a comprehensive collection of images and videos in our multimedia library.
Pfizer Inc. (NYSE:PFE) today announced that the comparative, confirmatory REFLECTIONS B538-02 study met its primary objective by demonstrating equivalent efficacy as measured by the American College of Rheumatology 20 (ACR20) response rate at Week 12. This trial is evaluating the efficacy, safety, and immunogenicity of PF-06410293 compared to Humira® (adalimumab), each taken in combination with methotrexate, in patients with moderate to severe rheumatoid arthritis. PF-06410293 is being developed as a potential biosimilar to Humira.
Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 31, 2017. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2016 Performance Report, to be issued that morning.
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Group President, Pfizer Innovative Health, Frank D’Amelio, Executive Vice President, Business Operations, and Chief Financial Officer, and Mikael Dolsten, President, Worldwide Research and Development, and at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017 at 10:30 a.m. Pacific Standard Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “35th Annual J.P.
Pfizer Inc. (NYSE:PFE) today announced that it has completed the acquisition of the development and commercialization rights to AstraZeneca’s late-stage small molecule anti-infective business, primarily outside the United States.
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for its first-in-class CDK 4/6 inhibitor, IBRANCE® (palbociclib).
Teleconference: Prevenar 13
Pfizer signs long-term agreement to supply Prevenar 13 to world's poorest countries.
Access the Pfizer Presentation Archive to view Executive Leadership presentations to shareholders, analysts, and global health care conferences.
Executive Speeches & Commentary
View Executive Leadership speeches on a variety of topics.
Pfizer Twitter Community
Stock Quote Disclaimer
20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.
Current Stock Price
|%Change||.||52 Wk. High||.|
|Day High||.||52 Wk. Low||.|
|Day Low||.||Mkt. Cap(Mil)||.|
Online Pfizer Press Kit
Our press kit provides information that might help you write stories or simply find out more about Pfizer.